| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Inflammatory Agents, Non-Steroidal | 30 | 2021 | 542 | 3.160 |
Why?
|
| Neoplasms | 73 | 2024 | 15952 | 2.840 |
Why?
|
| Colorectal Neoplasms | 43 | 2024 | 3707 | 2.590 |
Why?
|
| Aspirin | 15 | 2021 | 373 | 2.530 |
Why?
|
| Anticarcinogenic Agents | 29 | 2017 | 368 | 2.320 |
Why?
|
| Cyclooxygenase Inhibitors | 20 | 2017 | 177 | 2.160 |
Why?
|
| Health Promotion | 5 | 2024 | 508 | 2.080 |
Why?
|
| Adenoma | 22 | 2018 | 738 | 2.020 |
Why?
|
| Precancerous Conditions | 24 | 2024 | 1061 | 1.720 |
Why?
|
| Public Health | 5 | 2023 | 280 | 1.440 |
Why?
|
| Chemoprevention | 24 | 2015 | 251 | 1.420 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 18 | 2015 | 198 | 1.370 |
Why?
|
| Biomedical Research | 9 | 2018 | 800 | 1.190 |
Why?
|
| Celecoxib | 24 | 2018 | 198 | 1.100 |
Why?
|
| Clinical Trials as Topic | 21 | 2017 | 3841 | 1.000 |
Why?
|
| Early Detection of Cancer | 10 | 2024 | 1345 | 0.990 |
Why?
|
| Adenomatous Polyps | 5 | 2015 | 45 | 0.940 |
Why?
|
| Sulfonamides | 22 | 2012 | 1943 | 0.890 |
Why?
|
| Smoking | 12 | 2022 | 2549 | 0.850 |
Why?
|
| Pyrazoles | 22 | 2012 | 1551 | 0.840 |
Why?
|
| Colonic Polyps | 7 | 2020 | 228 | 0.820 |
Why?
|
| Eflornithine | 7 | 2015 | 60 | 0.790 |
Why?
|
| Primary Prevention | 4 | 2018 | 233 | 0.780 |
Why?
|
| Barrett Esophagus | 9 | 2014 | 560 | 0.780 |
Why?
|
| Humans | 195 | 2024 | 270809 | 0.770 |
Why?
|
| Electronic Nicotine Delivery Systems | 2 | 2019 | 77 | 0.760 |
Why?
|
| Isoenzymes | 9 | 2003 | 644 | 0.740 |
Why?
|
| Health Behavior | 2 | 2024 | 599 | 0.690 |
Why?
|
| Cancer Care Facilities | 3 | 2024 | 907 | 0.670 |
Why?
|
| Delivery of Health Care | 4 | 2022 | 850 | 0.660 |
Why?
|
| Tobacco Use Disorder | 1 | 2022 | 300 | 0.660 |
Why?
|
| Biomarkers, Tumor | 24 | 2022 | 10731 | 0.650 |
Why?
|
| Universities | 3 | 2024 | 159 | 0.650 |
Why?
|
| Carcinogens | 4 | 2019 | 390 | 0.640 |
Why?
|
| Colonoscopy | 9 | 2024 | 524 | 0.630 |
Why?
|
| Papillomavirus Vaccines | 2 | 2022 | 197 | 0.610 |
Why?
|
| Health Plan Implementation | 3 | 2020 | 82 | 0.590 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2014 | 825 | 0.590 |
Why?
|
| Minority Groups | 2 | 2024 | 325 | 0.580 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 11 | 2018 | 231 | 0.580 |
Why?
|
| Health Services | 1 | 2018 | 100 | 0.570 |
Why?
|
| Nicotine | 1 | 2019 | 265 | 0.570 |
Why?
|
| Sulindac | 7 | 2020 | 55 | 0.560 |
Why?
|
| Population Health | 1 | 2018 | 54 | 0.560 |
Why?
|
| Aromatase Inhibitors | 2 | 2018 | 311 | 0.550 |
Why?
|
| Blogging | 1 | 2016 | 2 | 0.550 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2016 | 629 | 0.540 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 6 | 2023 | 481 | 0.530 |
Why?
|
| Dinoprostone | 3 | 2015 | 219 | 0.520 |
Why?
|
| Esophageal Neoplasms | 10 | 2014 | 3241 | 0.520 |
Why?
|
| Prostaglandins | 2 | 2018 | 84 | 0.510 |
Why?
|
| Adenomatous Polyposis Coli | 9 | 2010 | 227 | 0.500 |
Why?
|
| Practice Guidelines as Topic | 8 | 2024 | 2395 | 0.500 |
Why?
|
| Adenocarcinoma | 12 | 2019 | 7920 | 0.490 |
Why?
|
| Exercise | 6 | 2024 | 1221 | 0.480 |
Why?
|
| National Institutes of Health (U.S.) | 5 | 2008 | 196 | 0.470 |
Why?
|
| United States | 20 | 2024 | 15834 | 0.470 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2014 | 453 | 0.470 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2024 | 2193 | 0.470 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 359 | 0.470 |
Why?
|
| Developing Countries | 1 | 2016 | 315 | 0.450 |
Why?
|
| Nanotechnology | 1 | 2014 | 136 | 0.440 |
Why?
|
| Research Design | 7 | 2015 | 1562 | 0.440 |
Why?
|
| Medical Oncology | 5 | 2019 | 1464 | 0.430 |
Why?
|
| Program Development | 3 | 2008 | 257 | 0.420 |
Why?
|
| Blood Platelets | 4 | 2018 | 675 | 0.410 |
Why?
|
| Obesity | 4 | 2023 | 2893 | 0.410 |
Why?
|
| Liver Neoplasms | 10 | 2024 | 4843 | 0.400 |
Why?
|
| Allopurinol | 1 | 2013 | 84 | 0.400 |
Why?
|
| Guideline Adherence | 1 | 2016 | 626 | 0.390 |
Why?
|
| Patient Selection | 6 | 2017 | 2032 | 0.390 |
Why?
|
| SEER Program | 2 | 2014 | 1052 | 0.380 |
Why?
|
| Liver Cirrhosis | 5 | 2024 | 1048 | 0.370 |
Why?
|
| Diet | 8 | 2024 | 1469 | 0.370 |
Why?
|
| Adult | 50 | 2024 | 82074 | 0.350 |
Why?
|
| Gastrointestinal Microbiome | 3 | 2024 | 972 | 0.340 |
Why?
|
| Cyclooxygenase 2 | 11 | 2017 | 496 | 0.340 |
Why?
|
| Research | 5 | 2019 | 421 | 0.330 |
Why?
|
| Female | 80 | 2024 | 148940 | 0.330 |
Why?
|
| Male | 77 | 2024 | 128522 | 0.320 |
Why?
|
| Colonic Neoplasms | 9 | 2010 | 1437 | 0.320 |
Why?
|
| Cancer Vaccines | 2 | 2011 | 759 | 0.310 |
Why?
|
| Middle Aged | 56 | 2024 | 90570 | 0.300 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 657 | 0.300 |
Why?
|
| Mass Screening | 5 | 2024 | 1547 | 0.300 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2022 | 219 | 0.290 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 819 | 0.290 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2022 | 1905 | 0.290 |
Why?
|
| Environmental Exposure | 2 | 2020 | 288 | 0.290 |
Why?
|
| Antineoplastic Agents | 19 | 2016 | 14639 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2024 | 5779 | 0.280 |
Why?
|
| Genome-Wide Association Study | 6 | 2024 | 2348 | 0.280 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 210 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 8 | 2024 | 2454 | 0.270 |
Why?
|
| Societies, Scientific | 2 | 2018 | 68 | 0.270 |
Why?
|
| Preoperative Care | 1 | 2013 | 1582 | 0.270 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2013 | 1347 | 0.270 |
Why?
|
| Disease Models, Animal | 7 | 2024 | 7323 | 0.260 |
Why?
|
| Molecular Targeted Therapy | 2 | 2016 | 2396 | 0.260 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2021 | 444 | 0.260 |
Why?
|
| Alopecia | 2 | 2001 | 125 | 0.260 |
Why?
|
| Drugs, Investigational | 2 | 2005 | 130 | 0.260 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2023 | 84 | 0.250 |
Why?
|
| Risk Factors | 23 | 2023 | 17867 | 0.250 |
Why?
|
| Cholagogues and Choleretics | 2 | 2004 | 38 | 0.250 |
Why?
|
| International Cooperation | 3 | 2018 | 326 | 0.240 |
Why?
|
| Ursodeoxycholic Acid | 2 | 2004 | 55 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2008 | 2659 | 0.240 |
Why?
|
| Incidence | 9 | 2024 | 5824 | 0.240 |
Why?
|
| Aged | 42 | 2024 | 73641 | 0.240 |
Why?
|
| Risk Assessment | 12 | 2017 | 6766 | 0.230 |
Why?
|
| Forecasting | 4 | 2016 | 699 | 0.230 |
Why?
|
| Case-Control Studies | 9 | 2024 | 6234 | 0.230 |
Why?
|
| Intestinal Mucosa | 6 | 2023 | 1112 | 0.230 |
Why?
|
| Hepatitis C Antibodies | 2 | 2024 | 49 | 0.230 |
Why?
|
| Preventive Medicine | 1 | 2004 | 32 | 0.230 |
Why?
|
| Texas | 9 | 2024 | 6445 | 0.230 |
Why?
|
| Animals | 35 | 2024 | 61363 | 0.230 |
Why?
|
| Cyclooxygenase 1 | 5 | 2017 | 67 | 0.230 |
Why?
|
| Carcinogenesis | 3 | 2020 | 1034 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 10 | 2024 | 4645 | 0.220 |
Why?
|
| Colon | 6 | 2006 | 684 | 0.220 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2024 | 55 | 0.220 |
Why?
|
| Mexico | 3 | 2021 | 260 | 0.220 |
Why?
|
| Membrane Proteins | 10 | 2013 | 2922 | 0.210 |
Why?
|
| Congresses as Topic | 2 | 2018 | 300 | 0.210 |
Why?
|
| Tobacco Products | 2 | 2022 | 157 | 0.210 |
Why?
|
| Models, Animal | 2 | 2005 | 657 | 0.210 |
Why?
|
| MicroRNAs | 2 | 2013 | 2884 | 0.210 |
Why?
|
| Politics | 1 | 2023 | 72 | 0.210 |
Why?
|
| Neoplasms, Experimental | 4 | 2005 | 784 | 0.210 |
Why?
|
| Smoking Prevention | 2 | 2024 | 143 | 0.210 |
Why?
|
| Societies, Medical | 3 | 2018 | 1323 | 0.200 |
Why?
|
| Tertiary Care Centers | 1 | 2024 | 419 | 0.200 |
Why?
|
| Life Style | 3 | 2016 | 617 | 0.190 |
Why?
|
| Carcinoma in Situ | 2 | 2022 | 489 | 0.190 |
Why?
|
| Amino Acids | 1 | 2024 | 746 | 0.190 |
Why?
|
| Students | 2 | 2021 | 334 | 0.190 |
Why?
|
| Risk | 7 | 2016 | 1931 | 0.190 |
Why?
|
| Hepacivirus | 2 | 2024 | 423 | 0.190 |
Why?
|
| Education, Distance | 1 | 2022 | 100 | 0.190 |
Why?
|
| Patient Navigation | 1 | 2021 | 33 | 0.190 |
Why?
|
| Mexican Americans | 2 | 2022 | 330 | 0.180 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2020 | 101 | 0.180 |
Why?
|
| Apoptosis | 7 | 2008 | 7757 | 0.180 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 172 | 0.180 |
Why?
|
| Conserved Sequence | 2 | 2012 | 497 | 0.180 |
Why?
|
| Vulvar Neoplasms | 1 | 2022 | 235 | 0.180 |
Why?
|
| Software Design | 3 | 2008 | 37 | 0.180 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 1404 | 0.180 |
Why?
|
| Gene Expression Profiling | 7 | 2023 | 5146 | 0.180 |
Why?
|
| Sigmoidoscopy | 2 | 2015 | 50 | 0.180 |
Why?
|
| Cultural Diversity | 2 | 2019 | 83 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2012 | 5053 | 0.170 |
Why?
|
| Placebos | 10 | 2011 | 439 | 0.170 |
Why?
|
| Bacteria | 1 | 2024 | 650 | 0.170 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2019 | 14 | 0.170 |
Why?
|
| Adolescent | 9 | 2024 | 32698 | 0.170 |
Why?
|
| Pesticides | 1 | 2019 | 25 | 0.170 |
Why?
|
| Disease Progression | 9 | 2021 | 6881 | 0.170 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2021 | 209 | 0.170 |
Why?
|
| Organophosphates | 1 | 2019 | 42 | 0.170 |
Why?
|
| Schools | 1 | 2021 | 238 | 0.170 |
Why?
|
| Tobacco Use Cessation | 1 | 2019 | 29 | 0.160 |
Why?
|
| Resistance Training | 1 | 2019 | 39 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 16752 | 0.160 |
Why?
|
| Smoking Cessation | 3 | 2024 | 770 | 0.160 |
Why?
|
| Serum Albumin, Bovine | 1 | 2019 | 84 | 0.160 |
Why?
|
| Cardiovascular Diseases | 9 | 2011 | 2220 | 0.160 |
Why?
|
| Vaping | 1 | 2019 | 45 | 0.160 |
Why?
|
| Breast Neoplasms | 8 | 2019 | 16246 | 0.160 |
Why?
|
| Health Communication | 1 | 2019 | 35 | 0.160 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 474 | 0.160 |
Why?
|
| Hepatitis C | 2 | 2024 | 548 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 3 | 2013 | 616 | 0.160 |
Why?
|
| Diplomacy | 1 | 2018 | 7 | 0.160 |
Why?
|
| Bile Duct Neoplasms | 1 | 2023 | 503 | 0.160 |
Why?
|
| Culture | 1 | 2019 | 104 | 0.160 |
Why?
|
| History, 21st Century | 2 | 2011 | 410 | 0.160 |
Why?
|
| Chronic Disease | 1 | 2024 | 1825 | 0.150 |
Why?
|
| Cholangiocarcinoma | 1 | 2023 | 506 | 0.150 |
Why?
|
| Patient Compliance | 2 | 2020 | 677 | 0.150 |
Why?
|
| Young Adult | 10 | 2024 | 22255 | 0.150 |
Why?
|
| Fatty Acids | 1 | 2021 | 437 | 0.150 |
Why?
|
| Smokers | 1 | 2019 | 154 | 0.150 |
Why?
|
| Nutrition Surveys | 1 | 2000 | 315 | 0.150 |
Why?
|
| History, 20th Century | 2 | 2011 | 533 | 0.150 |
Why?
|
| Carbon Isotopes | 1 | 2019 | 362 | 0.150 |
Why?
|
| Colitis, Ulcerative | 1 | 2001 | 260 | 0.150 |
Why?
|
| Selenomethionine | 3 | 2006 | 40 | 0.150 |
Why?
|
| Cigarette Smoking | 1 | 2019 | 104 | 0.150 |
Why?
|
| Lung | 2 | 2019 | 3287 | 0.140 |
Why?
|
| Genetic Variation | 4 | 2016 | 2157 | 0.140 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2017 | 95 | 0.140 |
Why?
|
| Double-Blind Method | 11 | 2012 | 2575 | 0.140 |
Why?
|
| American Cancer Society | 1 | 2016 | 35 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 515 | 0.140 |
Why?
|
| Biomarkers | 7 | 2018 | 5050 | 0.130 |
Why?
|
| Keratosis, Actinic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Overweight | 1 | 2020 | 484 | 0.130 |
Why?
|
| Bronchi | 3 | 2004 | 325 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 2 | 2016 | 443 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2019 | 434 | 0.130 |
Why?
|
| Endometrial Neoplasms | 2 | 2023 | 1386 | 0.130 |
Why?
|
| Trust | 1 | 2017 | 109 | 0.130 |
Why?
|
| Eicosanoids | 1 | 2015 | 29 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2018 | 321 | 0.130 |
Why?
|
| Drug Design | 4 | 2003 | 371 | 0.130 |
Why?
|
| Physicians | 1 | 2024 | 854 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 250 | 0.120 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 746 | 0.120 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 5 | 2010 | 2478 | 0.120 |
Why?
|
| Cohort Studies | 8 | 2021 | 9464 | 0.120 |
Why?
|
| Genotype | 8 | 2017 | 4249 | 0.120 |
Why?
|
| Periodicals as Topic | 2 | 2008 | 316 | 0.120 |
Why?
|
| Liver | 1 | 2024 | 3061 | 0.120 |
Why?
|
| Proteomics | 1 | 2022 | 1426 | 0.120 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 1225 | 0.120 |
Why?
|
| Nanomedicine | 1 | 2014 | 53 | 0.120 |
Why?
|
| Women | 1 | 2014 | 23 | 0.120 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 1250 | 0.120 |
Why?
|
| Gene Expression | 4 | 2006 | 3606 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 3 | 2014 | 1587 | 0.110 |
Why?
|
| Mutation | 6 | 2019 | 15922 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2022 | 999 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 4 | 2012 | 2442 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2016 | 5606 | 0.110 |
Why?
|
| Aged, 80 and over | 15 | 2020 | 31117 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 319 | 0.110 |
Why?
|
| Immunity, Cellular | 1 | 2015 | 436 | 0.110 |
Why?
|
| Prostatic Neoplasms | 4 | 2009 | 5870 | 0.110 |
Why?
|
| Glucose | 2 | 2018 | 1213 | 0.110 |
Why?
|
| Health Policy | 1 | 2016 | 277 | 0.110 |
Why?
|
| Biocompatible Materials | 1 | 2014 | 202 | 0.110 |
Why?
|
| Surveys and Questionnaires | 3 | 2021 | 5924 | 0.100 |
Why?
|
| Lipase | 1 | 2013 | 119 | 0.100 |
Why?
|
| Immune System | 1 | 2014 | 275 | 0.100 |
Why?
|
| Intestinal Neoplasms | 2 | 2008 | 205 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 3 | 2008 | 449 | 0.100 |
Why?
|
| Inflammation | 4 | 2018 | 2491 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2010 | 5264 | 0.100 |
Why?
|
| Aspartate Aminotransferases | 1 | 2012 | 145 | 0.100 |
Why?
|
| Mice | 13 | 2024 | 35421 | 0.100 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2012 | 29 | 0.100 |
Why?
|
| Wound Healing | 1 | 2017 | 771 | 0.100 |
Why?
|
| Upper Gastrointestinal Tract | 1 | 2012 | 19 | 0.100 |
Why?
|
| Liposomes | 1 | 2014 | 708 | 0.100 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 186 | 0.100 |
Why?
|
| Insurance Coverage | 1 | 2014 | 275 | 0.100 |
Why?
|
| beta Catenin | 1 | 2016 | 689 | 0.100 |
Why?
|
| Alanine Transaminase | 1 | 2012 | 236 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2019 | 747 | 0.100 |
Why?
|
| Amines | 1 | 2012 | 82 | 0.100 |
Why?
|
| Follow-Up Studies | 9 | 2018 | 15280 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1416 | 0.100 |
Why?
|
| Meat | 1 | 2012 | 91 | 0.100 |
Why?
|
| Heterocyclic Compounds | 1 | 2012 | 117 | 0.100 |
Why?
|
| Occult Blood | 2 | 2020 | 63 | 0.100 |
Why?
|
| Aging | 2 | 2015 | 1531 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2019 | 1216 | 0.090 |
Why?
|
| Glucuronosyltransferase | 1 | 2011 | 104 | 0.090 |
Why?
|
| Genes, APC | 2 | 2001 | 72 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 4495 | 0.090 |
Why?
|
| Vascular Diseases | 1 | 2013 | 234 | 0.090 |
Why?
|
| Enalapril | 1 | 2010 | 20 | 0.090 |
Why?
|
| Poverty | 1 | 2014 | 485 | 0.090 |
Why?
|
| Neoplasm Staging | 7 | 2020 | 14037 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1076 | 0.090 |
Why?
|
| Prospective Studies | 6 | 2022 | 13422 | 0.090 |
Why?
|
| Digestive System Neoplasms | 1 | 2000 | 79 | 0.090 |
Why?
|
| Lipoxygenase Inhibitors | 2 | 2000 | 24 | 0.090 |
Why?
|
| Drug Discovery | 1 | 2013 | 329 | 0.090 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 1336 | 0.090 |
Why?
|
| Esophagus | 3 | 2013 | 562 | 0.090 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 663 | 0.090 |
Why?
|
| Survivors | 1 | 2015 | 1022 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2012 | 244 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 1381 | 0.090 |
Why?
|
| Lipoxygenase | 2 | 2018 | 25 | 0.090 |
Why?
|
| Feces | 2 | 2024 | 852 | 0.080 |
Why?
|
| Genomics | 2 | 2017 | 2834 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2015 | 2227 | 0.080 |
Why?
|
| Signal Transduction | 5 | 2016 | 12036 | 0.080 |
Why?
|
| History, 18th Century | 1 | 2009 | 86 | 0.080 |
Why?
|
| Selenium | 1 | 2009 | 51 | 0.080 |
Why?
|
| Medicare | 1 | 2014 | 925 | 0.080 |
Why?
|
| Biological Products | 1 | 2013 | 318 | 0.080 |
Why?
|
| Proteome | 2 | 2004 | 571 | 0.080 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1195 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2015 | 2033 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2009 | 143 | 0.080 |
Why?
|
| Vitamin E | 1 | 2009 | 132 | 0.080 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2009 | 82 | 0.080 |
Why?
|
| Government Programs | 1 | 2008 | 16 | 0.080 |
Why?
|
| Transcriptome | 2 | 2018 | 1960 | 0.080 |
Why?
|
| Drug Therapy, Combination | 3 | 2010 | 2344 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2018 | 10409 | 0.080 |
Why?
|
| Government Regulation | 1 | 2008 | 58 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2007 | 312 | 0.080 |
Why?
|
| Pravastatin | 1 | 2008 | 33 | 0.080 |
Why?
|
| Ornithine Decarboxylase Inhibitors | 3 | 2004 | 18 | 0.080 |
Why?
|
| Lovastatin | 1 | 2008 | 56 | 0.080 |
Why?
|
| Phenotype | 3 | 2018 | 6503 | 0.080 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 12045 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 555 | 0.070 |
Why?
|
| Simvastatin | 1 | 2008 | 99 | 0.070 |
Why?
|
| Models, Biological | 4 | 2008 | 3187 | 0.070 |
Why?
|
| Telemedicine | 1 | 2014 | 557 | 0.070 |
Why?
|
| Decision Making | 1 | 2014 | 1249 | 0.070 |
Why?
|
| Intestinal Polyps | 2 | 2008 | 79 | 0.070 |
Why?
|
| Publishing | 1 | 2008 | 193 | 0.070 |
Why?
|
| Hyperplasia | 2 | 2019 | 571 | 0.070 |
Why?
|
| Diagnostic Imaging | 2 | 2007 | 1175 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2012 | 5099 | 0.070 |
Why?
|
| Genetic Heterogeneity | 2 | 2019 | 338 | 0.070 |
Why?
|
| Global Health | 2 | 2023 | 672 | 0.060 |
Why?
|
| Rats | 6 | 2012 | 6397 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2013 | 2769 | 0.060 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 627 | 0.060 |
Why?
|
| Internship and Residency | 1 | 2016 | 1445 | 0.060 |
Why?
|
| Treatment Outcome | 11 | 2017 | 33860 | 0.060 |
Why?
|
| Intestinal Polyposis | 1 | 2004 | 29 | 0.060 |
Why?
|
| Budesonide | 1 | 2004 | 35 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 4900 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1276 | 0.060 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 3534 | 0.060 |
Why?
|
| Energy Metabolism | 1 | 2010 | 985 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 2363 | 0.060 |
Why?
|
| Colon, Descending | 1 | 2003 | 8 | 0.060 |
Why?
|
| Colon, Ascending | 1 | 2003 | 14 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 1027 | 0.050 |
Why?
|
| Metagenome | 1 | 2024 | 193 | 0.050 |
Why?
|
| North America | 1 | 2024 | 337 | 0.050 |
Why?
|
| Chromosome Aberrations | 1 | 2010 | 2035 | 0.050 |
Why?
|
| Cameroon | 1 | 2022 | 14 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2020 | 2855 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 76 | 0.050 |
Why?
|
| Anethole Trithione | 1 | 2002 | 1 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2004 | 297 | 0.050 |
Why?
|
| Sexual and Gender Minorities | 1 | 2024 | 78 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 264 | 0.050 |
Why?
|
| Prognosis | 6 | 2018 | 22533 | 0.050 |
Why?
|
| Azoxymethane | 2 | 1999 | 44 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2024 | 248 | 0.050 |
Why?
|
| Hearing Loss | 1 | 2004 | 176 | 0.050 |
Why?
|
| Bronchodilator Agents | 1 | 2004 | 225 | 0.050 |
Why?
|
| Antioxidants | 3 | 2001 | 519 | 0.050 |
Why?
|
| Emigration and Immigration | 1 | 2002 | 91 | 0.050 |
Why?
|
| Cell Division | 3 | 2002 | 2657 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 57 | 0.050 |
Why?
|
| Bacteroidetes | 1 | 2021 | 23 | 0.050 |
Why?
|
| Enterobacteriaceae | 1 | 2022 | 53 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2004 | 1355 | 0.050 |
Why?
|
| Physical Fitness | 1 | 2002 | 126 | 0.050 |
Why?
|
| Calcium, Dietary | 1 | 2002 | 53 | 0.050 |
Why?
|
| Sensitivity and Specificity | 4 | 2009 | 5157 | 0.050 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2006 | 517 | 0.050 |
Why?
|
| Reproducibility of Results | 4 | 2008 | 6193 | 0.050 |
Why?
|
| Program Evaluation | 1 | 2024 | 602 | 0.050 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2023 | 333 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 501 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2012 | 592 | 0.050 |
Why?
|
| Dietary Fiber | 1 | 2002 | 129 | 0.050 |
Why?
|
| Duodenal Neoplasms | 1 | 2002 | 139 | 0.050 |
Why?
|
| Leadership | 1 | 2024 | 271 | 0.050 |
Why?
|
| Colombia | 1 | 2021 | 61 | 0.050 |
Why?
|
| Age of Onset | 2 | 2015 | 853 | 0.050 |
Why?
|
| Tissue Distribution | 2 | 2019 | 920 | 0.050 |
Why?
|
| Genetic Markers | 1 | 2004 | 1073 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2001 | 432 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2000 | 503 | 0.040 |
Why?
|
| Piroxicam | 1 | 2000 | 5 | 0.040 |
Why?
|
| Biopsy | 4 | 2017 | 3490 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2006 | 1555 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 2356 | 0.040 |
Why?
|
| Brazil | 1 | 2020 | 163 | 0.040 |
Why?
|
| Mouth Mucosa | 1 | 2001 | 223 | 0.040 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2001 | 142 | 0.040 |
Why?
|
| Learning | 1 | 2024 | 438 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2002 | 340 | 0.040 |
Why?
|
| Attitude | 1 | 2021 | 161 | 0.040 |
Why?
|
| Ki-67 Antigen | 4 | 2004 | 676 | 0.040 |
Why?
|
| Phospholipids | 1 | 2020 | 167 | 0.040 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4966 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 7054 | 0.040 |
Why?
|
| Prevalence | 3 | 2020 | 3395 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 5 | 2004 | 694 | 0.040 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2020 | 120 | 0.040 |
Why?
|
| DNA Repair | 2 | 2004 | 1906 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 1999 | 122 | 0.040 |
Why?
|
| Allelic Imbalance | 1 | 2019 | 41 | 0.040 |
Why?
|
| Folic Acid | 1 | 2001 | 370 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2000 | 326 | 0.040 |
Why?
|
| Hepatitis C, Chronic | 1 | 2024 | 472 | 0.040 |
Why?
|
| Capital Financing | 1 | 2018 | 11 | 0.040 |
Why?
|
| Thromboxane-A Synthase | 1 | 2018 | 26 | 0.040 |
Why?
|
| Hydrolysis | 1 | 2019 | 236 | 0.040 |
Why?
|
| Receptors, Prostaglandin | 1 | 2018 | 33 | 0.040 |
Why?
|
| Health Planning | 1 | 2018 | 28 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 566 | 0.040 |
Why?
|
| Bronchial Neoplasms | 1 | 1999 | 82 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 64 | 0.040 |
Why?
|
| Mixed Function Oxygenases | 1 | 2018 | 70 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7789 | 0.040 |
Why?
|
| Latin America | 1 | 2018 | 117 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2000 | 561 | 0.040 |
Why?
|
| Epoprostenol | 1 | 2018 | 86 | 0.040 |
Why?
|
| Aromatase | 1 | 1998 | 56 | 0.040 |
Why?
|
| Pyrazines | 1 | 2001 | 511 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 395 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 228 | 0.040 |
Why?
|
| Acetylation | 1 | 2019 | 516 | 0.040 |
Why?
|
| Cadherins | 2 | 2013 | 658 | 0.040 |
Why?
|
| Counseling | 1 | 2020 | 380 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 715 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 2001 | 530 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 853 | 0.030 |
Why?
|
| Ketoprofen | 1 | 1996 | 2 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 57 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2018 | 253 | 0.030 |
Why?
|
| Data Collection | 1 | 2019 | 602 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2024 | 912 | 0.030 |
Why?
|
| Logistic Models | 2 | 2019 | 3430 | 0.030 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 341 | 0.030 |
Why?
|
| Vaccination | 1 | 2022 | 1113 | 0.030 |
Why?
|
| Peptic Ulcer | 2 | 2012 | 161 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 854 | 0.030 |
Why?
|
| Haplotypes | 1 | 2019 | 908 | 0.030 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1998 | 347 | 0.030 |
Why?
|
| DNA | 2 | 2002 | 3041 | 0.030 |
Why?
|
| Odds Ratio | 3 | 2002 | 2300 | 0.030 |
Why?
|
| Patient Participation | 1 | 2020 | 454 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 1998 | 352 | 0.030 |
Why?
|
| Calcium | 1 | 2001 | 1571 | 0.030 |
Why?
|
| Mouth Neoplasms | 1 | 2001 | 736 | 0.030 |
Why?
|
| Mucous Membrane | 2 | 2006 | 258 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2004 | 1692 | 0.030 |
Why?
|
| Body Weight | 1 | 2020 | 1282 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2020 | 1254 | 0.030 |
Why?
|
| Paris | 1 | 2014 | 11 | 0.030 |
Why?
|
| China | 2 | 2006 | 628 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 2618 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 1944 | 0.030 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 588 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2020 | 2360 | 0.030 |
Why?
|
| Estrogens | 1 | 1998 | 804 | 0.030 |
Why?
|
| Probability | 2 | 2009 | 886 | 0.030 |
Why?
|
| Diclofenac | 1 | 2013 | 11 | 0.030 |
Why?
|
| Naproxen | 1 | 2013 | 25 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1999 | 1105 | 0.030 |
Why?
|
| Potassium Channels, Voltage-Gated | 1 | 2013 | 69 | 0.030 |
Why?
|
| Recurrence | 2 | 2012 | 4878 | 0.030 |
Why?
|
| Ibuprofen | 1 | 2013 | 53 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2001 | 2376 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2013 | 3463 | 0.030 |
Why?
|
| ADAM Proteins | 1 | 2013 | 114 | 0.030 |
Why?
|
| Models, Statistical | 1 | 2019 | 1187 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 674 | 0.030 |
Why?
|
| Taiwan | 1 | 2012 | 99 | 0.030 |
Why?
|
| Child | 3 | 2023 | 30572 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 14886 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2017 | 800 | 0.030 |
Why?
|
| Alleles | 1 | 2019 | 2598 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2212 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 1388 | 0.030 |
Why?
|
| Blood Vessels | 1 | 2013 | 232 | 0.020 |
Why?
|
| Cooking | 1 | 2012 | 68 | 0.020 |
Why?
|
| Proton Pump Inhibitors | 1 | 2014 | 272 | 0.020 |
Why?
|
| Neoplasm Proteins | 2 | 2004 | 3345 | 0.020 |
Why?
|
| Mass Spectrometry | 2 | 2004 | 721 | 0.020 |
Why?
|
| alpha-Fetoproteins | 1 | 2012 | 256 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2014 | 368 | 0.020 |
Why?
|
| Enzyme Induction | 2 | 2003 | 257 | 0.020 |
Why?
|
| CpG Islands | 1 | 2013 | 669 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 731 | 0.020 |
Why?
|
| Skin | 1 | 2016 | 1281 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 4993 | 0.020 |
Why?
|
| Gastrointestinal Tract | 1 | 2013 | 322 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 5332 | 0.020 |
Why?
|
| Alcohol Drinking | 2 | 2005 | 599 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Pharmacokinetics | 2 | 2000 | 40 | 0.020 |
Why?
|
| Survival Rate | 2 | 2013 | 12535 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2012 | 342 | 0.020 |
Why?
|
| Coronary Disease | 1 | 2013 | 741 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 1250 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 420 | 0.020 |
Why?
|
| Rats, Inbred F344 | 2 | 1999 | 235 | 0.020 |
Why?
|
| Authorship | 1 | 2008 | 48 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 14003 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 747 | 0.020 |
Why?
|
| Energy Intake | 1 | 2010 | 517 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 4971 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 267 | 0.020 |
Why?
|
| Algorithms | 2 | 2008 | 3908 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1127 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2008 | 273 | 0.020 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2006 | 44 | 0.020 |
Why?
|
| Quality of Life | 1 | 2021 | 4810 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2001 | 1592 | 0.020 |
Why?
|
| Sex Factors | 2 | 2004 | 2180 | 0.020 |
Why?
|
| Time Factors | 3 | 2012 | 12979 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 9281 | 0.020 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2005 | 72 | 0.020 |
Why?
|
| Carcinoma | 1 | 2017 | 2610 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 1155 | 0.020 |
Why?
|
| Safety | 1 | 2006 | 457 | 0.020 |
Why?
|
| Stroke | 1 | 2013 | 1061 | 0.020 |
Why?
|
| Tamoxifen | 2 | 1999 | 875 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2004 | 82 | 0.010 |
Why?
|
| Pharynx | 1 | 2004 | 148 | 0.010 |
Why?
|
| Risk Management | 1 | 2004 | 111 | 0.010 |
Why?
|
| Neoplastic Processes | 1 | 2003 | 15 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2004 | 206 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2004 | 179 | 0.010 |
Why?
|
| Headache | 1 | 2004 | 172 | 0.010 |
Why?
|
| Environment | 1 | 2004 | 170 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 2004 | 299 | 0.010 |
Why?
|
| Cough | 1 | 2004 | 125 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2007 | 6344 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1704 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1536 | 0.010 |
Why?
|
| Respiratory Mucosa | 1 | 2004 | 212 | 0.010 |
Why?
|
| Monitoring, Physiologic | 1 | 2006 | 515 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 586 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2050 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 17083 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2003 | 274 | 0.010 |
Why?
|
| Drug Approval | 1 | 2003 | 174 | 0.010 |
Why?
|
| Endoscopy | 1 | 2005 | 495 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 1188 | 0.010 |
Why?
|
| Thiones | 1 | 2001 | 19 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2006 | 679 | 0.010 |
Why?
|
| Methylation | 1 | 2003 | 625 | 0.010 |
Why?
|
| Metaplasia | 1 | 2002 | 387 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2004 | 7647 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2003 | 764 | 0.010 |
Why?
|
| Retinoids | 1 | 2001 | 152 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 2000 | 120 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10268 | 0.010 |
Why?
|
| Thiophenes | 1 | 2001 | 147 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 3582 | 0.010 |
Why?
|
| Carotenoids | 1 | 2001 | 104 | 0.010 |
Why?
|
| Esophageal Achalasia | 1 | 2000 | 41 | 0.010 |
Why?
|
| Half-Life | 1 | 2000 | 268 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2012 | 3671 | 0.010 |
Why?
|
| British Columbia | 1 | 1999 | 26 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2001 | 590 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 437 | 0.010 |
Why?
|
| Spirometry | 1 | 1999 | 153 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2000 | 650 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2003 | 1127 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 984 | 0.010 |
Why?
|
| Fluorescence | 1 | 1999 | 197 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1995 | 4810 | 0.010 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2000 | 118 | 0.010 |
Why?
|
| Scleroderma, Systemic | 1 | 2000 | 165 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1057 | 0.010 |
Why?
|
| Antimutagenic Agents | 1 | 1998 | 5 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2004 | 1544 | 0.010 |
Why?
|
| Fatigue | 1 | 2004 | 1292 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1999 | 355 | 0.010 |
Why?
|
| Remission Induction | 1 | 2004 | 3658 | 0.010 |
Why?
|
| Computers | 1 | 1998 | 132 | 0.010 |
Why?
|
| Pharmacology, Clinical | 1 | 1997 | 10 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 1462 | 0.010 |
Why?
|
| Dehydroepiandrosterone | 1 | 1997 | 33 | 0.010 |
Why?
|
| Epithelium | 1 | 1999 | 786 | 0.010 |
Why?
|
| Butylhydroxybutylnitrosamine | 1 | 1996 | 2 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 1715 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2000 | 746 | 0.010 |
Why?
|
| Fenretinide | 1 | 1997 | 100 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1996 | 117 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2001 | 1162 | 0.010 |
Why?
|
| Estrogen Antagonists | 1 | 1997 | 188 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1999 | 482 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2004 | 2084 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 9048 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 1996 | 481 | 0.010 |
Why?
|
| Bayes Theorem | 1 | 1998 | 1061 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3435 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 3656 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1999 | 1875 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2004 | 7233 | 0.010 |
Why?
|
| Prostate | 1 | 1996 | 1090 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2000 | 5692 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2013 | 39982 | 0.010 |
Why?
|
| Breast | 1 | 1996 | 1370 | 0.010 |
Why?
|
| Melanoma | 1 | 2005 | 5601 | 0.000 |
Why?
|
| Pregnancy | 1 | 2000 | 7917 | 0.000 |
Why?
|